X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
male (1230) 1230
humans (1193) 1193
index medicus (971) 971
hiv infections - drug therapy (792) 792
female (772) 772
animals (761) 761
benzoxazines - administration & dosage (661) 661
benzoxazines (617) 617
pharmacology & pharmacy (588) 588
adult (571) 571
rats (485) 485
anti-hiv agents - administration & dosage (450) 450
infectious diseases (450) 450
efavirenz (449) 449
morpholines - pharmacology (433) 433
naphthalenes - pharmacology (431) 431
benzoxazines - pharmacology (412) 412
benzoxazines - therapeutic use (380) 380
middle aged (371) 371
neurosciences (363) 363
anti-hiv agents - therapeutic use (359) 359
drug therapy, combination (327) 327
hiv (321) 321
dose-response relationship, drug (293) 293
treatment outcome (277) 277
immunology (272) 272
reverse transcriptase inhibitors - administration & dosage (264) 264
benzoxazines - adverse effects (263) 263
reverse transcriptase inhibitors - therapeutic use (241) 241
benzoxazines - pharmacokinetics (236) 236
anti-hiv agents - adverse effects (234) 234
rats, sprague-dawley (223) 223
oxazines - administration & dosage (222) 222
hiv infections - virology (217) 217
antiretroviral therapy (216) 216
drug administration schedule (214) 214
viral load (212) 212
mice (207) 207
antiviral agents (206) 206
piperidines - pharmacology (200) 200
pharmacokinetics (196) 196
drug therapy (195) 195
drug interactions (193) 193
pyrazoles - pharmacology (193) 193
rats, wistar (184) 184
hiv infection (177) 177
cd4 lymphocyte count (176) 176
dosage and administration (174) 174
oxazines - therapeutic use (174) 174
cannabinoids - pharmacology (172) 172
research (172) 172
time factors (171) 171
analysis (169) 169
virology (168) 168
therapy (166) 166
morpholines - administration & dosage (165) 165
naphthalenes - administration & dosage (165) 165
anti-hiv agents - pharmacokinetics (162) 162
hiv-1 - drug effects (155) 155
tenofovir (152) 152
microbiology (151) 151
adolescent (147) 147
nevirapine (146) 146
article (141) 141
cannabinoids (140) 140
receptor, cannabinoid, cb1 - agonists (138) 138
adenine - analogs & derivatives (136) 136
aged (136) 136
disease models, animal (136) 136
reverse transcriptase inhibitors - adverse effects (135) 135
lamivudine - administration & dosage (134) 134
human immunodeficiency virus--hiv (129) 129
young adult (128) 128
aids (120) 120
drug combinations (120) 120
antiretroviral drugs (118) 118
nevirapine - administration & dosage (118) 118
aids/hiv (115) 115
hiv-1 (112) 112
health aspects (110) 110
antiretroviral therapy, highly active (108) 108
cannabinoid (107) 107
care and treatment (106) 106
brain (105) 105
emtricitabine (105) 105
pharmacology (105) 105
adenine - administration & dosage (104) 104
highly active antiretroviral therapy (104) 104
oxazines - adverse effects (104) 104
hiv infections - complications (101) 101
analgesics - pharmacology (99) 99
nevirapine - therapeutic use (98) 98
reverse transcriptase inhibitors - pharmacokinetics (98) 98
receptor, cannabinoid, cb1 - metabolism (95) 95
ritonavir - administration & dosage (95) 95
lamivudine - therapeutic use (94) 94
safety (94) 94
psychiatry (93) 93
organophosphonates - administration & dosage (91) 91
prospective studies (91) 91
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1822) 1822
German (27) 27
Spanish (11) 11
French (10) 10
Japanese (4) 4
Italian (3) 3
Chinese (2) 2
Czech (1) 1
Hungarian (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


AIDS, ISSN 0269-9370, 09/2007, Volume 21, Issue 14, pp. 1899 - 1907
Objectives: To describe first dose and steady state antiretroviral drug exposure in the female genital tract. Design: Non-blinded, single center, open-label... 
Women | Genital tract | HIV | Prophylaxis | Sexual transmission | Pharmacokinetics | Antiretroviral therapy | genital tract | INFECTIOUS DISEASES | sexual transmission | antiretroviral therapy | EMTRICITABINE | IMMUNOLOGY | CEREBROSPINAL-FLUID | prophylaxis | BACTERIAL VAGINOSIS | PROTEASE INHIBITOR | TRICHOMONAS-VAGINALIS | HIV-INFECTION | THERAPY | VIROLOGY | LIQUID-CHROMATOGRAPHY | SIMIAN IMMUNODEFICIENCY VIRUS | pharmacokinetics | MACAQUES | women | Lamivudine - administration & dosage | Humans | Deoxycytidine - blood | Zidovudine - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | HIV Protease Inhibitors - pharmacokinetics | Atazanavir Sulfate | Genitalia, Female - metabolism | Emtricitabine | HIV Infections - blood | HIV Protease Inhibitors - blood | Adenine - analogs & derivatives | Pyridines - administration & dosage | Benzoxazines - administration & dosage | Administration, Oral | Anti-Retroviral Agents - pharmacokinetics | Deoxycytidine - administration & dosage | Lopinavir | HIV Protease Inhibitors - administration & dosage | Adenine - pharmacokinetics | Pyrimidinones - blood | Anti-Retroviral Agents - administration & dosage | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Zidovudine - blood | Deoxycytidine - analogs & derivatives | Reverse Transcriptase Inhibitors - blood | Zidovudine - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Adenine - blood | Reverse Transcriptase Inhibitors - pharmacokinetics | Benzoxazines - pharmacokinetics | Adult | Benzoxazines - blood | Female | Organophosphonates - blood | Anti-Retroviral Agents - blood | Drug Therapy, Combination | Oligopeptides - blood | Oligopeptides - pharmacokinetics | Lamivudine - blood | Lamivudine - pharmacokinetics | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Pyridines - blood | Pyrimidinones - pharmacokinetics | HIV Infections - drug therapy
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 238 - 246
Summary Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected... 
Internal Medicine | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | COMBINATION THERAPY | GUIDELINES | PROTEASE-INHIBITOR | ANTIRETROVIRAL THERAPY | NEVIRAPINE | REGIMENS | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Dosage and administration | Efavirenz | Patient outcomes | Clinical trials | Antiretroviral drugs | Drug therapy | Human immunodeficiency virus--HIV
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9835, pp. 2439 - 2448
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 6/2011, Volume 52, Issue 11, pp. 1374 - 1383
Background. The optimal time to initiate antiretroviral therapy (ART) in human immunodeficiency virus (HIV)—associated tuberculous meningitis is unknown.... 
Statistical median | HIV/AIDS | Antiretrovirals | Art therapy | Meningeal tuberculosis | HIV | Mortality | Random allocation | AIDS | Arts | HIV 1 | MORTALITY | SURVIVAL | THAILAND | INFECTIOUS DISEASES | HIV-INFECTION | ERA | ADOLESCENTS | CLINICAL-TRIALS | ADULTS | RISK | MICROBIOLOGY | IMMUNOLOGY | Lamivudine - administration & dosage | Humans | Antiretroviral Therapy, Highly Active - adverse effects | Male | Zidovudine - administration & dosage | Anti-HIV Agents - administration & dosage | Time Factors | Adult | Anti-Inflammatory Agents - administration & dosage | Female | HIV Infections - mortality | Antiretroviral Therapy, Highly Active - methods | Tuberculosis, Meningeal - mortality | Placebos - administration & dosage | Dexamethasone - administration & dosage | Tuberculosis, Meningeal - drug therapy | Benzoxazines - administration & dosage | Double-Blind Method | Trimethoprim, Sulfamethoxazole Drug Combination - administration & dosage | Anti-HIV Agents - adverse effects | Treatment Outcome | Tuberculosis, Meningeal - complications | HIV Infections - complications | Antitubercular Agents - administration & dosage | HIV Infections - drug therapy | Antiviral agents | Care and treatment | Patient outcomes | Dosage and administration | Drug therapy | Health aspects | HIV infection | Comorbid patients | Tuberculous meningitis
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 08/2008, Volume 52, Issue 7, pp. 569 - 576
Journal Article
AIDS (London, England), ISSN 0269-9370, 2013, Volume 27, Issue 5, pp. 803 - 813
To estimate the incidence of and risk factors for modifications to first antiretroviral therapy (ART) regimen, treatment interruption and death. A total of 21... 
HIV/AIDS | FRENCH-HOSPITAL-DATABASE | INFECTIOUS DISEASES | competing-risk method | VIROLOGICAL TREATMENT FAILURE | survival | AIDS | COMPETING RISKS | IMMUNOLOGY | DISCONTINUATION | switch | PROTEASE INHIBITOR | antiretroviral | VIROLOGY | ACTIVE ANTIRETROVIRAL THERAPY | interruption | SOCIETY-USA PANEL | INFECTED PATIENTS | COHORT | HIV-1 | United States - epidemiology | Lamivudine - administration & dosage | Humans | HIV Seropositivity - mortality | HIV Seropositivity - drug therapy | Nevirapine - adverse effects | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Adenine - adverse effects | Time Factors | Deoxycytidine - adverse effects | HIV Infections - mortality | Dideoxynucleosides - adverse effects | Antiretroviral Therapy, Highly Active - methods | Dideoxynucleosides - administration & dosage | Emtricitabine | HIV Protease Inhibitors - adverse effects | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Risk Factors | Organophosphonates - adverse effects | Europe - epidemiology | Benzoxazines - adverse effects | HIV Protease Inhibitors - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Lopinavir - administration & dosage | HIV Infections - drug therapy | Nevirapine - administration & dosage | Deoxycytidine - analogs & derivatives | Drug Combinations | Lopinavir - adverse effects | Cohort Studies
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 10/2008, Volume 198, Issue 8, pp. 1113 - 1122
Background. Vicriviroc (VCV) is a CCR5 antagonist with nanomolar activity against human immunodeficiency virus (HIV) replication in vitro and in vivo. We... 
HIV/AIDS | Tropisms | RNA | HIV | Placebos | Viruses | AIDS | Infections | Dosage | HIV 1 | Virology | INFECTIOUS DISEASES | MYOCARDIAL-INFARCTION | MICROBIOLOGY | IMMUNOLOGY | HUMAN-IMMUNODEFICIENCY-VIRUS | PROGNOSTIC VALUE | CCR5 ANTAGONIST | INDIVIDUALS | ANTIRETROVIRAL-DRUG-RESISTANCE | SYNCYTIUM-INDUCING PHENOTYPE | EPIDEMIOLOGY | DISEASE PROGRESSION | Piperazines - administration & dosage | Lamivudine - administration & dosage | Humans | Male | RNA, Viral - blood | Reverse Transcriptase Inhibitors - administration & dosage | Viral Load | Zidovudine - administration & dosage | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Reverse Transcriptase Inhibitors - adverse effects | HIV-1 - physiology | Lamivudine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | CCR5 Receptor Antagonists | Benzoxazines - administration & dosage | Double-Blind Method | Zidovudine - adverse effects | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | HIV Infections - virology | Benzoxazines - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Piperazines - therapeutic use | Piperazines - adverse effects | Benzoxazines - therapeutic use | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | HIV Infections - drug therapy | Zidovudine - therapeutic use | Lamivudine | Dosage and administration | HIV (Viruses) | Drug therapy | Zidovudine | Index Medicus | Abridged Index Medicus
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 05/2013, Volume 63, Issue 1, pp. 77 - 85
BACKGROUND:STARTMRK, a phase III noninferiority trial of raltegravir-based versus efavirenz-based therapy in treatment-naive patients, remained blinded until... 
raltegravir | HIV | STARTMRK | efavirenz | treatment naive | INFECTIOUS DISEASES | THERAPY | IMMUNOLOGY | HIV-1 INFECTION | SUBGROUP | Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination | HIV-1 | Oxazines | Humans | Male | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | Raltegravir Potassium | Emtricitabine | Pyrrolidinones - adverse effects | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Pyrrolidinones - therapeutic use | Benzoxazines - adverse effects | Treatment Outcome | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Deoxycytidine - analogs & derivatives | Drug Combinations
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 10/2011, Volume 53, Issue 8, pp. 807 - 816
Background. We compared 3 years of antiretroviral therapy with raltegravir or efavirenz as part of a combination regimen in the ongoing STARTMRK study of... 
HIV/AIDS | Antiretrovirals | Fasting | HIV | Body fat | Response rates | Viruses | Lipids | Fats | Virology | HIV 1 | INFECTIOUS DISEASES | RESISTANT HIV-1 INFECTION | MULTICENTER | EFFICACY | SAFETY | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | RANDOMIZED CONTROLLED-TRIAL | IMMUNOLOGY | THERAPY | DOUBLE-BLIND | LOPINAVIR/RITONAVIR | SUBGROUP | Humans | Male | RNA, Viral - blood | Viral Load | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Adenine - adverse effects | HIV-1 - isolation & purification | Adult | Deoxycytidine - adverse effects | Female | Drug Therapy, Combination | Raltegravir Potassium | Emtricitabine | Pyrrolidinones - adverse effects | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Absorptiometry, Photon | Adenine - administration & dosage | Organophosphonates - administration & dosage | Adolescent | HIV Infections - drug therapy | Deoxycytidine - analogs & derivatives | Usage | Drug utilization | HIV patients | Dosage and administration | Drug therapy, Combination | Drug therapy | Efavirenz | Raltegravir
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 2/2013, Volume 207, Issue 4, pp. 604 - 611
Background. The effect of nonthymidine nucleoside reverse-transcriptase inhibitors (NRTIs) on fat mitochondrial DNA (mtDNA) content and function is unclear.... 
Adipose tissues | Body mass index | Registered nurses | RNA | Oxidative phosphorylation | MAJOR ARTICLES AND BRIEF REPORTS | AIDS | Biopsies | Mitochondrial DNA | Fats | HIV 1 | CELLS | INFECTIOUS DISEASES | lipoatrophy | THYMIDINE ANALOG | MICROBIOLOGY | mitochondrial dysfunction | ANTIRETROVIRAL THERAPY | ACTG | IMMUNOLOGY | metabolic disease | oxidative phosphorylation | HIV-INFECTED PATIENTS | INHIBITION | mitochondrial toxicity | lipodystrophy | ADIPOSE-TISSUE | HIV-1 | Lamivudine - administration & dosage | DNA, Mitochondrial - drug effects | Humans | Male | Reverse Transcriptase Inhibitors - administration & dosage | Oligopeptides - therapeutic use | Anti-HIV Agents - administration & dosage | Tenofovir | Adipose Tissue - metabolism | Deoxycytidine - therapeutic use | DNA, Mitochondrial - genetics | Adenine - therapeutic use | Lamivudine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Dideoxynucleosides - therapeutic use | Reverse Transcriptase Inhibitors - therapeutic use | Drug Therapy, Combination | Pyridines - therapeutic use | Dideoxynucleosides - administration & dosage | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Benzoxazines - administration & dosage | DNA, Mitochondrial - metabolism | Organophosphonates - therapeutic use | Ritonavir - administration & dosage | Deoxycytidine - administration & dosage | HIV-Associated Lipodystrophy Syndrome - physiopathology | Treatment Outcome | Mitochondria - drug effects | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Adipose Tissue - drug effects | Deoxycytidine - analogs & derivatives | Drug Combinations | Care and treatment | Patient outcomes | Physiological aspects | Reverse transcriptase inhibitors | Dosage and administration | Research | HIV infection | Major and Brief Reports
Journal Article
Neurobiology of Learning and Memory, ISSN 1074-7427, 10/2016, Volume 134, pp. 264 - 274
The cannabinoid system plays an important role in memory processes, many studies have indicated that cannabinoid receptor ligands have ability to modulate... 
Hemopressin | (m)VD-hemopressin(α) | Recognition memory | (m)RVD-hemopressin(α) | Alzheimer’s disease | Cannabinoid receptor | Alzheimer's disease | Amyloid beta-Peptides - pharmacology | Male | Peptide Fragments - pharmacology | Cannabinoid Receptor Agonists - pharmacology | Hemoglobins - administration & dosage | Receptor, Cannabinoid, CB1 - agonists | Piperidines - pharmacology | Cannabinoid Receptor Antagonists - pharmacology | Behavior, Animal - drug effects | Amyloid beta-Peptides - administration & dosage | Hemoglobins - pharmacology | Alzheimer Disease - chemically induced | Disease Models, Animal | Pyrazoles - pharmacology | Piperidines - administration & dosage | Benzoxazines - administration & dosage | Morpholines - administration & dosage | Peptide Fragments - administration & dosage | Alzheimer Disease - drug therapy | Morpholines - pharmacology | Cannabinoid Receptor Agonists - administration & dosage | Naphthalenes - pharmacology | Pyrazoles - administration & dosage | Animals | Memory Disorders - drug therapy | Recognition (Psychology) - drug effects | Naphthalenes - administration & dosage | Benzoxazines - pharmacology | Cannabinoid Receptor Antagonists - administration & dosage | Mice | Oligopeptides - administration & dosage | Receptor, Cannabinoid, CB1 - antagonists & inhibitors | Infusions, Intraventricular | Oligopeptides - pharmacology | Memory Disorders - chemically induced
Journal Article
Journal of Neuroinflammation, ISSN 1742-2094, 01/2012, Volume 9, Issue 1, pp. 8 - 8
Background: Alzheimer's disease (AD) brain shows an ongoing inflammatory condition and non-steroidal anti-inflammatories diminish the risk of suffering the... 
Interleukin 6 | Cannabinoids | Glial activation | Anti-inflammatories | β-amyloid peptide | Tumor necrosis factor-α | Alzheimer's disease | ACTIVATION | CANNABIDIOL | ALZHEIMERS-DISEASE | MEMORY DEFICITS | beta-amyloid peptide | ENDOCANNABINOID SYSTEM | PATHOLOGY | IMMUNOLOGY | anti-inflammatories | NEUROSCIENCES | tumor necrosis factor-alpha | interleukin 6 | glial activation | IN-VIVO | PROTEIN EXPRESSION | cannabinoids | CENTRAL-NERVOUS-SYSTEM | RECEPTOR AGONIST | Encephalitis - prevention & control | Alzheimer Disease - complications | Cognition Disorders - diagnostic imaging | Encephalitis - diagnostic imaging | Humans | Choroid Plexus - metabolism | Fluorodeoxyglucose F18 - metabolism | Glycogen Synthase Kinase 3 beta | Positron-Emission Tomography | RNA, Messenger - metabolism | Corpus Striatum - metabolism | Cognition Disorders - prevention & control | Time Factors | Cyclooxygenase 2 - genetics | Cognition Disorders - etiology | Amyloid beta-Peptides - metabolism | Microglia - pathology | Disease Models, Animal | Benzoxazines - administration & dosage | Enzyme-Linked Immunosorbent Assay | Microglia - drug effects | Administration, Oral | Cannabinoids - administration & dosage | Choroid Plexus - pathology | Gene Expression Regulation - genetics | Morpholines - administration & dosage | Mice, Transgenic | Glycogen Synthase Kinase 3 - metabolism | Gene Expression Regulation - drug effects | Receptor, Cannabinoid, CB2 - metabolism | Amyloid beta-Protein Precursor - genetics | Animals | Analysis of Variance | Naphthalenes - administration & dosage | Cyclooxygenase 2 - metabolism | Corpus Striatum - drug effects | Mice | Alzheimer Disease - genetics | Encephalitis - etiology | tumor necrosis factor-α
Journal Article